Showing results (471-480 of 531) with videos related to

Sort By:
Pageof 54
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
The New England Journal of Medicine|December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaStephen J Schuster, Michael R Bishop, Constantine S Tam, et al.
Blood|September 8, 2023
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesZhiwei Ang, Luca Paruzzo, Katharina E Hayer, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2023
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesZhiwei Ang, Luca Paruzzo, Katharina E Hayer, et al.
The New England Journal of Medicine|January 24, 2014
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphomaAjay K Gopal, Brad S Kahl, Sven de Vos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2022
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomasG Ghilardi, E A Chong, J Svoboda, et al.
Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Haematologica|May 17, 2020
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomasJakub Svoboda, Steven M Bair, Daniel J Landsburg, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.
Pageof 54